STOCK TITAN

Acadia Pharmaceuticals (ACAD) DEF 14A Filings

ACAD NASDAQ

Here are the DEF 14A proxy statements from Acadia Pharmaceuticals Inc. (ACAD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ACAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAD filings page.

Rhea-AI Summary

Acadia Pharmaceuticals is holding its 2026 annual stockholder meeting virtually on May 29, 2026 at 8:00 a.m. Pacific time. Stockholders of record as of April 14, 2026 may vote online on several key items.

Proposals include electing three Class I directors to serve until the 2029 meeting, an advisory “say-on-pay” vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to increase the shares authorized for issuance by 5,209,670, adjust the counting ratio for full-value awards, and raise the maximum shares available for incentive stock options. The Board recommends voting “FOR” all four proposals.